In March of this year, Oklahoma resolved their claims against Purdue Pharma LP the OxyContin maker for $270 million. They also successfully won against Teva Pharmaceutical Industries Ltd recently for $85 million.Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. Stay Informed! Stay Competitive! Join us at Vista Partners! It’s FREE to receive email updates.
Oklahoma Attorney General Mike Hunter Files Multibillion-dollar “Opioid” Case Against J&J
Reportedly Johnson & Johnson (JNJ) has been accused of using deceitful methods to encourage the over-use of opioid painkillers that has led to a U.S. opioid epidemic. Mike Hunter, Oklahoma Attorney General recently filed a multi-billion dollar case demanding J&J to pay for helping cause the “worst manmade public health crisis in our state’s history.” In defense, J&J lawyer Larry Ottway has been reported to have put forward the argument that opioids were U.S. Food and Drug Administration approved and their packaging contained labels warning of the addictive risk. He also added that their opioids made up a small portion prescribed overall.week8(2)